Atossa Therapeutics announced the appointment of Eric Van Zanten as Vice President of Investor and Public Relations. Prior to joining Atossa, Mr. Van Zanten led corporate affairs at Faron Pharmaceuticals, a clinical stage biopharmaceutical company focused on tackling difficult-to-treat cancers via precision macrophage immunotherapy and Urogen Pharma, a commercial stage biotech delivering innovative solutions that treat specialty cancers.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ATOS:
- Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations
- Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
- Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy
- Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.
- Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
